Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 4, 2014, Pages 654-664

  Carpentier, C ^a,b   Ghanem, D ^a,b   Fernandez Gomez, F J ^a,b   Jumeau, F ^a,b   Philippe, J V ^c   Freyermuth, F ^d   Labudeck, A ^a,b   Eddarkaoui, S ^a,b   Dhaenens, C M ^a,b   Holt, I ^e,f   Behm Ansmant, I ^c   Marmier Gourrier, N ^c   Branlant, C ^c   Charlet Berguerand, N ^d   Marie, J ^g   Schraen Maschke, S ^a,b   Buee L ^a,b   Sergeant, N ^a,b   Caillet Boudin, M L ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Biopôle de l Université de Lorraine   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^f KEELE UNIVERSITY   (United Kingdom)

^g SORBONNE UNIVERSITÉ   (France)

Author keywords

Microtubule associated protein Tau; Muscleblind like protein; Myotonic dystrophy; Splicing; Tauopathies

Indexed keywords

CIS ACTING ELEMENT; MBNL1 PROTEIN; MBNL2 PROTEIN; MEMBRANE PROTEIN; NUCLEOTIDE; TAU PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; EXON; HUMAN; HUMAN CELL; MYOTONIC DYSTROPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SENSITIVITY ANALYSIS; TRINUCLEOTIDE REPEAT;

MICROTUBULE-ASSOCIATED PROTEIN TAU; MUSCLEBLIND-LIKE PROTEIN; MYOTONIC DYSTROPHY; SPLICING; TAUOPATHIES;

BASE SEQUENCE; CELL LINE, TUMOR; EXONS; HUMANS; MOLECULAR SEQUENCE DATA; MYOTONIC DYSTROPHY; RESPONSE ELEMENTS; RNA SPLICING; RNA-BINDING PROTEINS; TAU PROTEINS;

EID: 84893453434     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.01.004     Document Type: Article

References (40)

1. Schara U., Schoser B.G.H. Myotonic dystrophies type 1 and 2: a summary on current aspects. Semin. Pediatr. Neurol. 2006, 13:71-79.
2. Sicot G., Gourdon G., Gomes-Pereira M. Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges. Hum. Mol. Genet. 2011, 20:116-123.
3. Sergeant N., Bretteville A., Hamdane M., Caillet-Boudin M.L., Grognet P., Bombois S., Blum D., Delacourte A., Pasquier F., Vanmechelen E., Schraen-Maschke S., Buée L. Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev. Proteomics 2008, 5:207-224.
4. Sergeant N., Sablonnière B., Schraen-Maschke S., Ghestem A., Maurage C.A., Wattez A., Vermersch P., Delacourte A. Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum. Mol. Genet. 2001, 10:2143-2155.
5. Leroy O., Wang J., Maurage C.-A., Parent M., Cooper T., Buée L., Sergeant N., Andreadis A., Caillet-Boudin M.L. Brain-specific change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1. Biochim. Biophys. Acta 2006, 1762:460-467.
6. Jiang H., Mankodi A., Swanson M.S., Moxley R.T., Thornton C.A. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 2004, 13:3079-3088.
7. Dhaenens C.M., Schraen-Maschke S., Tran H., Vingtdeux V., Ghanem D., Leroy O., Delplanque J., Vanbrussel E., Delacourte A., Vermersch P., Maurage C.A., Gruffat H., Sergeant A., Mahadevan M.S., Ishiura S., Buée L., Cooper T.A., Caillet-Boudin M.L., Charlet-Berguerand N., Sablonnière B., Sergeant N. Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats. Exp. Neurol. 2008, 210:467-478.
8. Maurage C.A., Udd B., Ruchoux M.M., Vermersch P., Kalimo H., Krahe R., Delacourte A., Sergeant N. Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease. Neurology 2005, 65:1636-1638.
9. Buée L., Troquier L., Burnouf S., Belarbi K., Van der Jeugd A., Ahmed T., Fernandez-Gomez F., Caillierez R., Grosjean M.E., Begard S., Barbot B., Demeyer D., Obriot H., Brion I., Buée-Scherrer V., Maurage C.A., Balschun D., D'hooge R., Hamdane M., Blum D., Sergeant N. From tau phosphorylation to tau aggregation: what about neuronal death?. Biochem. Soc. Trans. 2010, 38:967-972.
10. Niblock M., Gallo J.M. Tau alternative splicing in familial and sporadic tauopathies. Biochem. Soc. Trans. 2012, 40(4):677-680.
11. Fardaei M., Rogers M.T., Thorpe H.M., Larkin K., Hamshere M.G., Harper P.S., Brook J.D. Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum. Mol. Genet. 2002, 11:805-814.
12. Adereth Y., Dammai V., Kose N., Li R., Hsu T. RNA-dependent integrin alpha3 protein localization regulated by the Muscleblind-like protein MLP1. Nat. Cell Biol. 2005, 7:1240-1247.
13. Wang E.T., Cody N.A.L., Jog S., Biancolella M., Wang T.T., Treacy D.J., Luo S., Schroth G.P., Housman D.E., Reddy S., Lécuyer E., Burge C. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 2012, 150:710-724.
14. Pascual M., Vicente M., Monferrer L., Artero R. The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing. Differentiation 2006, 74:65-80.
15. Ranum L.P.W., Cooper T.A. RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci. 2012, 29:259-277.
16. Dasgupta T., Ladd A.N. The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins. Wiley Interdiscip. Rev. RNA 2012, 3:104-121.
17. Leroy O., Dhaenens C.M., Schraen-Maschke S., Belarbi K., Delacourte A., Andreadis A., et al. ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I. J. Neurosci. Res. 2006, 84:852-859.
18. Dhaenens C.M., Tran H., Frandemiche M.L., Carpentier C., Schraen-Maschke S., Sistiaga A., et al. Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing. Biochim. Biophys. Acta 2011, 1812:732-742.
19. Charizanis K., Lee K.Y., Batra R., Goodwin M., Zhang C., Yuan Y., Shiue L., Cline M., Scotti M.M., Xia G., Kumar A., Ashizawa T., Clark H.B., Kimura T., Takahashi M.P., Fujimura H., Jinnai K., Yoshikawa H., Gomes-Pereira M., Gourdon G., Sakai N., Nishino S., Foster T.C., Ares M., Darnell R.B., Swanson M.S. Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron 2012, 75:437-450.
20. Suenaga K., Lee K.Y., Nakamori M., Tatsumi Y., Takahashi M.P., Fujimura H., Jinnai K., Yoshikawa H., Du H., Ares M., Swanson M.S., Kimura T. Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain. PLoS ONE 2012, 7:193-218.
21. Kanadia R.N., Johnstone K.A., Mankodi A., Lungu C., Thornton C.A., Esson D., Timmers A.M., Hauswirth W.W., Swanson M.S. A muscleblind knockout model for myotonic dystrophy. Science 2003, 302:1978-1980.
22. Kino Y., Mori D., Oma Y., Takeshita Y., Sasagawa N., Ishiura S. Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats. Hum. Mol. Genet. 2004, 13:495-507.
23. Warf M.B., Berglund J.A. MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T. RNA 2007, 13:2238-2251.
24. Tran H., Gourrier N., Lemercier-Neuillet C., Dhaenens C.M., Vautrin A., Fernandez-Gomez F.J., Arandel L., Carpentier C., Obriot H., Eddarkaoui S., Delattre L., Van Brussels E., Holt I., Morris G.E., Sablonnière B., Buée L., Charlet-Berguerand N., Schraen-Maschke S., Furling D., Behm-Ansmant I., Branlant C., Caillet-Boudin M.L., Sergeant N. Analysis of exonic regions involved in nuclear localization, splicing activity, and dimerization of Muscleblind-like-1 isoforms. J. Biol. Chem. 2011, 286:16435-16446.
25. Lin X., Miller J.W., Mankodi A., Kanadia R.N., Yuan Y., Moxley R.T., Swanson M., Thorton C. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 2006, 15:2087-2097.
26. Philips A.V., Timchenko L.T., Cooper T.A. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998, 280:737-741.
27. Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9:671-675.
28. Ghanem D., Tran H., Dhaenens C.M., Schraen-Maschke S., Sablonnière B., Buée L., Sergeant N., Caillet-Boudin M.L. Altered splicing of Tau in DM1 is different from the foetal splicing process. FEBS Lett. 2009, 583:675-679.
29. Piva F., Giulietti M., Burini A.B., Principato G. SpliceAid 2: a database of human splicing factors expression data and RNA target motifs. Hum. Mutat. 2012, 33:81-85.
30. Chamberlain C.M., Ranum L.P.W. Mouse model of muscleblind-like 1 overexpression: skeletal muscle effects and therapeutic promise. Hum. Mol. Genet. 2012, 21:4645-4654.
31. Kanadia R.N., Shin J., Yuan Y., Beattie S.G., Wheeler T.M., Thornton C.A., Swanson M.S. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc. Natl. Acad. Sci. 2006, 103:11748-11753.
32. Goers E.S., Purcell J., Voelker R.B., Gates D.P., Berglund J.A. MBNL1 binds GC motifs embedded in pyrimidines to regulate alternative splicing. Nucleic Acids Res. 2010, 38:2467-2484.
33. Li K., Arikan M.C., Andreadis A. Modulation of the membrane-binding domain of tau protein: splicing regulation of exon 2. Brain Res. Mol. 2003, 116:94-105.
34. Lovci M.T., Ghanem D., Marr H., Arnold J., Gee S., Parra M., Liang T.Y., Stark T.J., Gehman L.T., Hoon S., Massirer K.B., Pratt G.A., Black D.L., Gray J.W., Conboy J.G., Yeo G.W. Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges. Nat. Struct. Mol. Biol. 2013, 20:1434-1442.
35. Zhang C., Lee K.Y., Swanson M.S., Darnell R.B. Prediction of clustered RNA-binding protein motif sites in the mammalian genome. Nucleic Acids Res. 2013, 14:6793-6807.
36. Grammatikakis I., Goo Y.H., Echeverria G.V., Cooper TA T.A. Identification of MBNL1 and MBNL3 domains required for splicing activation and repression. Nucleic Acids Res. 2011, 39:2769-2780.
37. Fugier C., Klein A.F., Hammer C., Vassilopoulos S., Ivarsson Y., Toussaint A., Tosch V., Vignaud A., Ferry A., Messaddeq, Kokunai Y., Tsuburaya R., De la Grange P., Dembele D., François V., Precigout G., Boulade-Ladame C., Hummel M.C., Lopez A., Sergeant N., Laquerrière A., Thibault C., Deryckere F., Auboeuf D., Garcia L., Zimmermann P., Udd B., Schoser B., Takahashi M., Nishino I., Bassez G., Laporte J., Furling D., Charlet-Berguerand N. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat. Med. 2011, 17:720-725.
38. Echeverria G.V., Cooper T.A. Muscleblind-like 1 activates insulin receptor exon 11 inclusion by enhancing U2AF65 binding and splicing of the upstream intron. Nucleic Acids Res. 2014, (accepted for publication). 10.1093/nar/gkt1020.
39. Dansithong W., Paul S., Comai L., Reddy S. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J. Biol. Chem. 2005, 280:5773-5780.
40. Han H., Irimia M., Ross P.J., Sung H.K., Alipanahi B., David L., Golipour A., Gabut M., Michael I.P., Nachman E.N., Wang E., Trcka D., Thompson T., O'Hanlon D., Slobodeniuc V., Barbosa-Morais N.L., Burge C.B., Moffat J., Frey B.J., Nagy A., Ellis J., Wrana J.L., Blencowe B.J. MBNL proteins repress ES-cell-specific alternative splicing and reprogramming. Nature 2013, 498:241-245.